Evidence map›Paper›PMID 27102814›Full record

ArticleJournal of experimental & clinical cancer research : CR2016

Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.

Zheng Hu, Guixiang Lv, Yongning Li, Enze Li, Haixia Li, Qi Zhou, Bin Yang, Wenwu Cao

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Ultrasound cavitation enhanced chemotherapy:Experimental biology and medicine (Maywood, N.J.) · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Zheng HuLaboratory of Sono- and Photo-theranostic Technologies, Harbin Institute of Technology, Harbin, 150080, China.
Guixiang LvDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, 150086, China.
Yongning LiLaboratory of Sono- and Photo-theranostic Technologies, Harbin Institute of Technology, Harbin, 150080, China.
Enze LiLaboratory of Sono- and Photo-theranostic Technologies, Harbin Institute of Technology, Harbin, 150080, China.
Haixia LiDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, 150086, China.
Qi ZhouLaboratory of Sono- and Photo-theranostic Technologies, Harbin Institute of Technology, Harbin, 150080, China.
Bin YangLaboratory of Sono- and Photo-theranostic Technologies, Harbin Institute of Technology, Harbin, 150080, China.
Wenwu CaoLaboratory of Sono- and Photo-theranostic Technologies, Harbin Institute of Technology, Harbin, 150080, China. dzk@psu.edu.
Harbin Institute of Technology · CNHarbin Medical University · CNPennsylvania State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) accounts for 75% of liver cancers and is the second most lethal cancer, associated with its multiple etiologies, poor prognosis and resistance to chemotherapy drugs. Chemotherapy treatment on HCC suffers low efficacy of drug uptake and can produce a range of side effects. Here we report an investigation on the effect of a combined treatment on human hepatocellular carcinoma BEL-7402 cells using low-intensity ultrasound (US) and 5-fluorouracil (5-FU).

methodsThe uptake of 5-FU was measured by the high-performance liquid chromatography (HPLC). DNA damage was detected by the comet assay. MTT assay was used to examine cell viability. Intracellular reactive oxygen species (ROS) and mitochondrial membrane potential (Δψm) were respectively detected by the fluorescent probes DCFH-DA or JC-1. Endogenous apoptosis-associated proteins were analyzed by the western blot and immunohistochemistry. Histopathological changes were evaluated by the hematoxylin and eosin (H&E) staining. Cell apoptosis was evaluated by the TUNEL and flow cytometry assays. Cell proliferation was measured using the immunohistochemical staining of PCNA.

resultsOur results showed that low-intensity US (1.1 MHz, 1.0 W/cm2, 10% duty cycle) significantly enhanced the uptake of 5-FU, 5-FU-mediated DNA damage and reactive oxygen species (ROS) generation. The increased ROS production up-regulated the p53 protein level, which led to the up-regulation of Bax and down-regulation of Bcl-2. The enhancement of ROS generation and the activation of the apoptosis-associated proteins further triggered the collapse of mitochondrial membrane potential, released cytochrome c from mitochondria into cytosol and activated the mitochondria-caspase pathway, and cell apoptosis. Such enhanced effects could be partially blocked by the ROS scavenger N-acetylcysteine (NAC). Overall, low-intensity US combined with 5-FU led to an effective inhibition of tumor growth and prolonged overall survival of BEL-7402 HCC-bearing nude mice by more than 15% compared with 5-FU treatment alone.

conclusionsOur results showed that low-intensity ultrasound combined with 5-FU produced much enhanced synergistic anti-tumor effects via enhanced ROS production in treating HCC.

Indexed as

AnimalsAntimetabolites, AntineoplasticCarcinoma, HepatocellularCell Line, TumorCell ProliferationCell SurvivalCombined Modality TherapyDown-RegulationFluorouracilGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMembrane Potential, MitochondrialMiceReactive Oxygen SpeciesAntimetabolites, AntineoplasticFluorouracilReactive Oxygen Species5-fluorouracilAnti-tumor effectsHepatocellular carcinomaLow-intensity ultrasoundReactive oxygen species

Identifiers

PMID27102814
PMCPMC4840943
OpenAlexW2338698464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.